ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results

被引：0
|
作者：
Strober, Bruce [1 ]
Crowley, Jeffrey [2 ]
Valdes, Joaquin [3 ]
Gu, Yihua [3 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Bakersfield Dermatol, Bakersfield, CA USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2011年 / 64卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB155 / AB155
页数：1
相关论文
共 50 条
  • [21] Safety update of etanercept treatment for moderate to severe plaque psoriasis
    Campanati, Anna
    Diotallevi, Federico
    Martina, Emanuela
    Paolinelli, Matteo
    Radi, Giulia
    Offidani, Annamaria
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (04) : 439 - 448
  • [22] Safety and efficacy of efalizumab therapy for elderly patients with moderate to severe chronic plaque psoriasis
    Gottlieb, A
    Lizzul, P
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P194 - P194
  • [23] Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis
    Leonardi, C
    Goffe, B
    Sobell, J
    Caro, I
    Wang, X
    Papp, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A58 - A58
  • [24] A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis
    Lebwohl, Mark G.
    Kircik, Leon
    Duffin, Kristina Callis
    Pariser, David
    Hooper, Michele
    Wenkert, Deborah
    Thompson, Elizabeth H. Z.
    Yang, Jun
    Kricorian, Greg
    Koo, John
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) : 385 - 392
  • [25] Efficacy and safety of etanercept in moderate to severe plaque psoriasis using two different dosing regimens
    Mazzotta, A
    Costanzo, A
    Giunta, A
    Chimenti, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB201 - AB201
  • [26] Characterization of etanercept pharmacokinetics, immunogenicity, and efficacy in pediatric patients with moderate to severe plaque psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Gary
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB67 - AB67
  • [27] Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
    Valenzuela, F.
    Paul, C.
    Mallbris, L.
    Tan, H.
    Papacharalambous, J.
    Valdez, H.
    Mamolo, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1753 - 1759
  • [28] Safety and efficacy study on etanercept in patients with plaque psoriasis
    Costanzo, A
    Mazzotta, A
    Papoutsaki, M
    Chimenti, S
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (01) : 187 - 189
  • [29] Efficacy and safety of secukinumab in moderate to severe plaque psoriasis
    Aparicio Rubio, Celia
    Monteagudo Santolaya, Emilio
    Cornejo Uixeda, Silvia
    Prieto Castello, Manuel
    Antonino de la Camara, Gonzalo
    Quintana Vergara, Belen
    Sanchez Alcaraz, Agustin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 299 - 299
  • [30] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
12345